Biomarkers /
CDKN2C
Back to Biomarkers List
Overview
Cyclin-dependent kinase inhibitor 2C (CDKN2C, also known as p18) is a gene that encodes a protein that inhibits the activation of CDK 4 and CDK6. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as bone cancer, endometrial cancer, and intestinal cancer.
CDKN2C is altered in 0.71% of all cancers with conventional glioblastoma multiforme, lung adenocarcinoma, glioblastoma, colon adenocarcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in CDKN2C are CDKN2C Mutation (0.35%), CDKN2C Loss (0.23%), CDKN2C Amplification (0.12%), CDKN2C Nonsense (0.04%), and CDKN2C Fusion (0.01%) [3].
Clinical Trials
Significance of CDKN2C in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
